Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244082 · ClinicalTrials.gov registry record · Phase 2
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
A Phase 2 study of Duchenne Muscular Dystrophy and DMD, sponsored by Avidity Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 10
- Study locations
NCT06244082: Active Phase 2 study of Duchenne Muscular Dystrophy and DMD, sponsored by Avidity Biosciences.
NCT06244082 is a Phase 2 study of Duchenne Muscular Dystrophy and DMD that is active but no longer recruiting, run by Avidity Biosciences. The registered enrollment target is 39 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06244082, a Phase 2 study of Duchenne Muscular Dystrophy and DMD, is active but no longer recruiting, sponsored by Avidity Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 10
- Study locations
Study Summary
AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
Conditions Studied
Interventions
- DRUG AOC 1044
Study Locations (10)
California
- University of California, San Diego, Rady's Children's Hospital - La Jolla
- UC Davis Medical Center - Sacramento
- Lucille Packard Children's Hospital at Stanford - San Carlos
Arkansas
- Arkansas Children's Hospital - Little Rock
Georgia
- Rare Disease Research - Atlanta - Atlanta
Massachusetts
- University of Massachusetts Medical School - Worcester
Minnesota
- Gillette Children's Specialty Healthcare - Saint Paul
North Carolina
- Rare Disease Research - Hillsborough
Ohio
- Abigail Wexner Research Institute at Nationwide Children's Hospital - Columbus
Texas
- Neurology Rare Disease Center - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
What the registry record for NCT06244082 still lists
NCT06244082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which AOC 1044 is the first listed.
NCT06244082 lists 10 locations in 8 states (California, Arkansas, Georgia).
Frequently Asked Questions
What is clinical trial NCT06244082 about?
NCT06244082 is a clinical study titled "Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping". AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
What is the current status of trial NCT06244082?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-01-22. Estimated completion is 2027-07-31.
What conditions does trial NCT06244082 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, DMD, Exon 44, Duchenne.
What interventions are being tested in trial NCT06244082?
The interventions under investigation include: AOC 1044 (DRUG).
Who is sponsoring clinical trial NCT06244082?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244082 being conducted?
This trial has 10 study locations across Arkansas, California, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06244082's enrollment target sits among peer trials
39 30th of 48 higher than 18 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
RECRUITING · Phase 2
-
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI